InvestorsHub Logo
Followers 3
Posts 354
Boards Moderated 0
Alias Born 11/03/2017

Re: thesaud post# 10202

Wednesday, 02/07/2018 6:18:15 PM

Wednesday, February 07, 2018 6:18:15 PM

Post# of 44784
Hi Saud, Pluristem may have little control over the ARS trial, but they do have a certain degree of control over how information is communicated to the shareholder. I cannot understand this delay and it does not make sense to me either. I also do not understand what is going on in Japan.

This is a quote from the latest financial statement:

"In December 2015, we reached an agreement with Japan’s Pharmaceuticals and Medical Devices Agency on the design of the final trial needed to apply for conditional approval of PLX-PAD cells in the treatment of CLI. The approval of the protocol for the 75-patient trial was part of a larger agreement on the development of PLX-PAD via Japan’s new accelerated regulatory pathway for regenerative medicine [my emphasis].

On the one hand Japan offers a new accelerated regulatory pathway for therapies such as Pluristem's and on the other hand as far as I understand it, no trial seems to be currently happening. This does not make sense to me.

It pains me to say this, but there appears to have been a certain lack of transparency in the way certain things have been communicated and I do not like it. This is obviously my personal view and others may feel differently.

Regards,

HB